杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2025/04/01 | 1,505 | 1,520 | 1,493 | 1,498 | -4 | -0.3% | 100,800 |
| 2025/03/31 | 1,531 | 1,532 | 1,502 | 1,502 | -56 | -3.6% | 162,800 |
| 2025/03/28 | 1,563 | 1,577 | 1,557 | 1,558 | -28 | -1.8% | 89,500 |
| 2025/03/27 | 1,580 | 1,586 | 1,563 | 1,586 | +5 | +0.3% | 114,300 |
| 2025/03/26 | 1,583 | 1,586 | 1,568 | 1,581 | -3 | -0.2% | 111,400 |
| 2025/03/25 | 1,560 | 1,584 | 1,557 | 1,584 | +28 | +1.8% | 167,800 |
| 2025/03/24 | 1,587 | 1,587 | 1,556 | 1,556 | -37 | -2.3% | 172,100 |
| 2025/03/21 | 1,594 | 1,603 | 1,586 | 1,593 | -3 | -0.2% | 114,600 |
| 2025/03/19 | 1,603 | 1,607 | 1,595 | 1,596 | -4 | -0.3% | 66,200 |
| 2025/03/18 | 1,597 | 1,613 | 1,597 | 1,600 | +3 | +0.2% | 103,900 |
| 2025/03/17 | 1,597 | 1,609 | 1,590 | 1,597 | +5 | +0.3% | 106,900 |
| 2025/03/14 | 1,597 | 1,610 | 1,591 | 1,592 | -4 | -0.3% | 105,400 |
| 2025/03/13 | 1,612 | 1,613 | 1,589 | 1,596 | -16 | -1% | 98,000 |
| 2025/03/12 | 1,598 | 1,623 | 1,595 | 1,612 | +12 | +0.8% | 196,000 |
| 2025/03/11 | 1,575 | 1,615 | 1,573 | 1,600 | +24 | +1.5% | 225,700 |
| 2025/03/10 | 1,587 | 1,592 | 1,571 | 1,576 | -17 | -1.1% | 139,200 |
| 2025/03/07 | 1,553 | 1,610 | 1,547 | 1,593 | +21 | +1.3% | 314,400 |
| 2025/03/06 | 1,618 | 1,632 | 1,548 | 1,572 | -86 | -5.2% | 518,100 |
| 2025/03/05 | 1,680 | 1,698 | 1,561 | 1,658 | -19 | -1.1% | 1,910,800 |
| 2025/03/04 | 1,677 | 1,677 | 1,677 | 1,677 | +300 | +21.8% | 122,700 |
| 2025/03/03 | 1,388 | 1,390 | 1,371 | 1,377 | +7 | +0.5% | 60,000 |
| 2025/02/28 | 1,381 | 1,383 | 1,362 | 1,370 | -11 | -0.8% | 112,300 |
| 2025/02/27 | 1,374 | 1,384 | 1,371 | 1,381 | +3 | +0.2% | 51,900 |
| 2025/02/26 | 1,360 | 1,381 | 1,360 | 1,378 | +24 | +1.8% | 98,500 |
| 2025/02/25 | 1,343 | 1,359 | 1,333 | 1,354 | +11 | +0.8% | 138,300 |
| 2025/02/21 | 1,339 | 1,344 | 1,331 | 1,343 | +2 | +0.1% | 119,200 |
| 2025/02/20 | 1,362 | 1,362 | 1,340 | 1,341 | -25 | -1.8% | 152,700 |
| 2025/02/19 | 1,372 | 1,385 | 1,361 | 1,366 | -5 | -0.4% | 56,800 |
| 2025/02/18 | 1,373 | 1,389 | 1,366 | 1,371 | -6 | -0.4% | 50,200 |
| 2025/02/17 | 1,386 | 1,388 | 1,376 | 1,377 | -9 | -0.6% | 45,600 |
| 2025/02/14 | 1,393 | 1,394 | 1,380 | 1,386 | -1 | -0.1% | 51,400 |
| 2025/02/13 | 1,371 | 1,393 | 1,371 | 1,387 | +25 | +1.8% | 69,800 |
| 2025/02/12 | 1,397 | 1,397 | 1,362 | 1,362 | -22 | -1.6% | 122,900 |
| 2025/02/10 | 1,387 | 1,388 | 1,376 | 1,384 | +11 | +0.8% | 57,100 |
| 2025/02/07 | 1,385 | 1,401 | 1,371 | 1,373 | -10 | -0.7% | 151,500 |
| 2025/02/06 | 1,400 | 1,400 | 1,376 | 1,383 | -39 | -2.7% | 240,300 |
| 2025/02/05 | 1,430 | 1,439 | 1,422 | 1,422 | -7 | -0.5% | 118,400 |
| 2025/02/04 | 1,435 | 1,446 | 1,428 | 1,429 | +1 | +0.1% | 75,500 |
| 2025/02/03 | 1,462 | 1,466 | 1,424 | 1,428 | -44 | -3% | 200,500 |
| 2025/01/31 | 1,473 | 1,473 | 1,464 | 1,472 | -2 | -0.1% | 66,400 |
| 2025/01/30 | 1,463 | 1,474 | 1,460 | 1,474 | +6 | +0.4% | 80,900 |
| 2025/01/29 | 1,470 | 1,473 | 1,463 | 1,468 | -4 | -0.3% | 45,400 |
| 2025/01/28 | 1,470 | 1,482 | 1,462 | 1,472 | +1 | +0.1% | 49,700 |
| 2025/01/27 | 1,457 | 1,472 | 1,457 | 1,471 | +14 | +1% | 46,100 |
| 2025/01/24 | 1,445 | 1,457 | 1,443 | 1,457 | +17 | +1.2% | 83,400 |
| 2025/01/23 | 1,442 | 1,443 | 1,435 | 1,440 | ±0 | ±0% | 70,900 |
| 2025/01/22 | 1,450 | 1,451 | 1,440 | 1,440 | -2 | -0.1% | 52,700 |
| 2025/01/21 | 1,451 | 1,454 | 1,442 | 1,442 | ±0 | ±0% | 32,700 |
| 2025/01/20 | 1,441 | 1,455 | 1,441 | 1,442 | +2 | +0.1% | 36,000 |
| 2025/01/17 | 1,444 | 1,445 | 1,437 | 1,440 | -6 | -0.4% | 61,200 |
1～
50
件表示中 / 3670件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 148,000円 | +3.2% | +4.5% | 3.51% | 17.00倍 | 0.65倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| 持田薬 | 319,000円 | +3.0% | +27.5% | 2.51% | 20.19倍 | 0.87倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
| ジーエヌアイ | 203,100円 | +21.7% | +999.9% | 0.00% | 8.46倍 | 2.80倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
| 栄研化 | 226,400円 | +0.4% | -8.4% | 2.34% | 29.07倍 | 1.66倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
| ネクセラファーマ | 87,500円 | +22.8% | - | 0.00% | 71.49倍 | 1.15倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
市場注目の銘柄
チャート関連のコラム
